Oncologist: Real-world assessment of the impact of age at diagnosis on the treatment and prognosis of metastatic pancreatic ductal adenocarcinoma

Studies have shown that 68% of pancreatic ductal adenocarcinoma (PDAC) patients are 65 years of age or older
.

At the same time, older adults are underrepresented in clinical trials, and their treatment is complicated by multiple age-related diseases

Studies have shown that 68% of pancreatic ductal adenocarcinoma (PDAC) patients are 65 years of age or older

Data on patients diagnosed with mPDAC between January 1, 2015, and March 31, 2020 were extracted from the Flatiron Health database
.

Patients were divided into 3 age groups: <70 years, 70-79 years, and ≥80 years

Data on patients diagnosed with mPDAC between January 1, 2015, and March 31, 2020 were extracted from the Flatiron Health database

Of the 8382 enrolled patients, 71.

Overall, 71.

Across all age groups, the most common first-line treatment was gemcitabine plus nab-paclitaxel
.

First-line gemcitabine monotherapy accounts for nearly a quarter of the treatment regimen for patients ≥80 years of age, but is less frequently used for patients <80 years of age

Across all age groups, the most common first-line treatment was gemcitabine plus nab-paclitaxel

Among patients receiving at least first-line therapy, median OS decreased significantly with age
.

Among patients receiving at least first-line therapy, median OS decreased significantly with age
.

Among patients receiving at least first-line therapy, median OS decreased significantly with age

Median OS was 7.
9 months (95% CI, 7.
6-8.
3 months) for patients aged <70 years, 6.
8 months (95% CI, 6.
3-7.
2 months) for patients 70-79 years, and 80 years of patients at 6.
2 months (95% CI, 5.
5-6.
8 months) (p<0.
0001)
.

However, when comparing survival outcomes across treatment regimens, median OS was similar across age groups

Median OS was 7.

Taken together, this study demonstrates that elderly patients with mPDAC can greatly benefit from receiving an appropriate treatment regimen
.

Taken together, this study demonstrates that elderly patients with mPDAC can greatly benefit from receiving an appropriate treatment regimen
.
This study shows that elderly patients with mPDAC can greatly benefit from receiving an appropriate treatment regimen
.
This study shows that elderly patients with mPDAC can greatly benefit from receiving an appropriate treatment regimen
.

 

Original source:

Original source:

Elias R, Cockrum P, Surinach A, Wang S, Chul Chu B, Shahrokni A.
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Oncologist.
2022 Mar 12:oyac028.
doi : 10.
1093/oncolo/oyac028.
Epub ahead of print.
PMID: 35278079.

Elias R, Cockrum P, Surinach A, Wang S, Chul Chu B, Shahrokni A.
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Oncologist.
2022 Mar 12:oyac028.
doi : 10.
1093/oncolo/oyac028.
Epub ahead of print.
PMID: 35278079.

 

 

 

leave a message here